Search clinical trials for: olaparib durvalumab

Total 1084 results

Nordic Society of Gynaecological Oncology - Clinical...
Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)

Ovarian Cancer

Denmark
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Duke University
AstraZeneca

Completed

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

Triple Negative Breast Cancer

United States
National University Hospital, Singapore

Recruiting

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies (MEDIPAC)

Solid Tumor, Adult

Singapore
AGO Research GmbH

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Epithelial Ovarian Cancer

Germany
Centre Georges Francois Leclerc
AstraZeneca

Active, not recruiting

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)

Immunotherapy

France
Yonsei University
Samsung Medical Center; AstraZeneca; Seoul National University Hospital; Korean... and other collaborators

Recruiting

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Platinum-resistant Recurrent Ovarian Cancer

Korea, Republic of
AstraZeneca

Active, not recruiting

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Germany, Austria, Israel, Australia
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc; The European Network for...

Active, not recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Endometrial Neoplasms

United States, Belgium, Canada, Germany, Korea, Republic of, Brazil, Hungary, Japan, Poland, Russian Federation, China, Hong Kong, Spain, Israel, Australia, India, Singapore, Greece, Estonia, Lithuania, Mexico, Colombia
Li Zhang, MD

Recruiting

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Small Cell Lung Cancer | Lung Cancer | Durvalumab

China
European Organisation for Research and Treatment...
AstraZeneca

Withdrawn

Chemo-free BRCA-targeted Neoadjuvant Strategy

BRCA1 Mutation | BRCA2 Mutation | TNBC - Triple-Negative Breast Cancer
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
ARCAGY/ GINECO GROUP

Active, not recruiting

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (BOLD)

Epithelial Ovarian Cancer | Relapse

France
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
Fondazione Ricerca Traslazionale

Recruiting

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients

Italy
Asan Medical Center

Recruiting

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM)

Biliary Tract Cancer | DNA Damage Repair Deficiency

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Terminated

A Study of Olaparib and Durvalumab in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
Spanish Oncology Genito-Urinary Group
AstraZeneca; Apices Soluciones S.L.; Sistemas Genómicos

Completed

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) (NEODURVARIB)

Bladder Cancer

Spain
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Latin American Cooperative Oncology Group

Terminated

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Bladder Cancer | Urothelial Carcinoma

Brazil
Seoul National University Hospital

Active, not recruiting

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
University Health Network, Toronto

Recruiting

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID)

Glioma | Solid Tumor | Cholangiocarcinoma | IDH Mutation

Canada
Seoul National University Hospital
AstraZeneca

Active, not recruiting

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Breast Neoplasms

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer

United States
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad... and other collaborators

Active, not recruiting

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

Advanced Ovarian Cancer

Canada, Denmark, Germany, Italy, Spain, United States, Belgium, Poland, France, Korea, Republic of, Brazil, Hungary, Japan, Peru, Turkey, China, Austria, Bulgaria, Finland, Romania
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Active, not recruiting

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
AstraZeneca

Active, not recruiting

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) (BAYOU)

Urinary Bladder Neoplasms

United States, Spain, Canada, Taiwan, Vietnam, Korea, Republic of, Russian Federation
AstraZeneca
Merck Sharp & Dohme LLC; Iqvia Pty Ltd

Completed

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (IVIVC)

Malignant Solid Tumor

Belgium
Hellenic Cooperative Oncology Group
AstraZeneca

Completed

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. (OPHELIA)

Squamous Cell Carcinoma of the Head and Neck

Greece
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Breast Neoplasms | Colorectal Neoplasms

United States
GERCOR - Multidisciplinary Oncology Cooperative...
AstraZeneca

Active, not recruiting

Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (MAZEPPA)

Metastatic Pancreatic Adenocarcinoma

France
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
Dana-Farber Cancer Institute
Novartis; AstraZeneca

Completed

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
Do-Youn Oh
AstraZeneca

Active, not recruiting

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Advanced Gastric Cancer

Korea, Republic of
University Health Network, Toronto
AstraZeneca

Active, not recruiting

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)

Pancreatic Adenocarcinoma | Leiomyosarcoma | Mismatch Repair Proficient Colorectal Cancer

Canada
AstraZeneca
Kappa Santé

Recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (ARSENAL)

Small Cell Lung Carcinoma

France
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Completed

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)

Epithelial Ovarian Cancer

Denmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
CCTU- Cancer Theme
AstraZeneca; Cancer Research UK; University of Cambridge

Recruiting

WIRE - Novel Treatments in Renal Cell Cancer (WIRE)

Renal Cell Cancer

United Kingdom
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Yonsei University

Completed

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sarcoma

Korea, Republic of

Search clinical trials for: olaparib durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations